Oncternal Net Invested Capital vs Total Liab Analysis
ONCT Stock | USD 9.21 0.11 1.21% |
Oncternal Therapeutics financial indicator trend analysis is much more than just breaking down Oncternal Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Oncternal Therapeutics is a good investment. Please check the relationship between Oncternal Therapeutics Net Invested Capital and its Total Liab accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncternal Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Oncternal Stock please use our How to Invest in Oncternal Therapeutics guide.
Net Invested Capital vs Total Liab
Net Invested Capital vs Total Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Oncternal Therapeutics Net Invested Capital account and Total Liab. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Oncternal Therapeutics' Net Invested Capital and Total Liab is -0.14. Overlapping area represents the amount of variation of Net Invested Capital that can explain the historical movement of Total Liab in the same time period over historical financial statements of Oncternal Therapeutics, assuming nothing else is changed. The correlation between historical values of Oncternal Therapeutics' Net Invested Capital and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Invested Capital of Oncternal Therapeutics are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Net Invested Capital i.e., Oncternal Therapeutics' Net Invested Capital and Total Liab go up and down completely randomly.
Correlation Coefficient | -0.14 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Net Invested Capital
The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Most indicators from Oncternal Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Oncternal Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncternal Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Oncternal Stock please use our How to Invest in Oncternal Therapeutics guide.Sales General And Administrative To Revenue is likely to gain to 16.78 in 2024, whereas Selling General Administrative is likely to drop slightly above 9.5 M in 2024.
2010 | 2023 | 2024 (projected) | Reconciled Depreciation | 47K | 41.4K | 37.2K | Discontinued Operations | 13.9M | 12.5M | 11.1M |
Oncternal Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Oncternal Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Oncternal Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 21.7M | 118.8M | 93.6M | 68.7M | 36.7M | 61.3M | |
Total Stockholder Equity | 14.3M | (82.8M) | (114.1M) | (158.3M) | 30.1M | 31.6M | |
Net Debt | (19.9M) | (116.7M) | (90.7M) | (37.1M) | (6.4M) | (6.7M) | |
Retained Earnings | (65.6M) | (82.8M) | (114.1M) | (158.3M) | (197.8M) | (207.7M) | |
Cash | 20.1M | 116.7M | 90.8M | 37.1M | 6.7M | 6.4M | |
Other Assets | 767K | 806K | 657K | 1.3M | 1.1M | 1.7M | |
Cash And Short Term Investments | 20.1M | 116.7M | 90.8M | 63.7M | 34.3M | 55.2M | |
Common Stock Shares Outstanding | 516.4K | 1.0M | 2.5M | 2.6M | 2.9M | 3.1M | |
Liabilities And Stockholders Equity | 21.7M | (76.9M) | (108.7M) | 68.7M | 36.7M | 31.8M | |
Other Stockholder Equity | 628.8M | 79.9M | (49K) | (66K) | 227.8M | 294.2M | |
Total Liab | 7.4M | 5.9M | 5.5M | 7.7M | 6.7M | 6.3M | |
Total Current Assets | 20.8M | 118.0M | 92.9M | 67.3M | 36.1M | 58.6M | |
Other Current Liab | 2.7M | 3.0M | 3.4M | 4.7M | 3.9M | 7.3M | |
Total Current Liabilities | 7.3M | 5.9M | 5.5M | 7.7M | 5.2M | 4.9M | |
Property Plant And Equipment Net | 190K | 40K | 75K | 87K | 258K | 245.1K | |
Accounts Payable | 871K | 1.1M | 2.0M | 2.9M | 1.1M | 1.6M | |
Non Current Assets Total | 957K | 806K | 732K | 1.4M | 670K | 636.5K | |
Common Stock Total Equity | 24K | 15K | 49K | 57K | 65.6K | 50.6K | |
Non Current Liabilities Total | 91K | 2.8M | 2.0M | 3.0M | 1.5M | 1.4M | |
Property Plant And Equipment Gross | 190K | 40K | 75K | 87K | 258K | 245.1K | |
Common Stock | 24K | 15K | 49K | 57K | 3K | 2.9K | |
Non Currrent Assets Other | 767K | 766K | 657K | 1.3M | 412K | 428.8K | |
Accumulated Other Comprehensive Income | (2.7M) | (2.6M) | 0.0 | 9K | 3K | 3.2K | |
Net Tangible Assets | 14.4M | 113.0M | 88.1M | 61.0M | 70.1M | 35.9M | |
Retained Earnings Total Equity | (600.1M) | (65.6M) | (82.8M) | (158.3M) | (182.0M) | (191.1M) | |
Capital Surpluse | 626.1M | 79.9M | 195.7M | 219.2M | 197.3M | 340.7M | |
Property Plant Equipment | 190K | 40K | 75K | 87K | 78.3K | 152.8K | |
Net Invested Capital | 14.3M | 113.0M | 88.1M | 61.0M | 30.1M | 58.3M | |
Net Working Capital | 13.4M | 112.1M | 87.4M | 59.6M | 30.9M | 57.8M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncternal Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Oncternal Stock please use our How to Invest in Oncternal Therapeutics guide.Note that the Oncternal Therapeutics information on this page should be used as a complementary analysis to other Oncternal Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Complementary Tools for Oncternal Stock analysis
When running Oncternal Therapeutics' price analysis, check to measure Oncternal Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncternal Therapeutics is operating at the current time. Most of Oncternal Therapeutics' value examination focuses on studying past and present price action to predict the probability of Oncternal Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncternal Therapeutics' price. Additionally, you may evaluate how the addition of Oncternal Therapeutics to your portfolios can decrease your overall portfolio volatility.
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Transaction History View history of all your transactions and understand their impact on performance | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |
Is Oncternal Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncternal Therapeutics. If investors know Oncternal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncternal Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (12.33) | Revenue Per Share 0.39 | Quarterly Revenue Growth 1.803 | Return On Assets (0.49) | Return On Equity (0.87) |
The market value of Oncternal Therapeutics is measured differently than its book value, which is the value of Oncternal that is recorded on the company's balance sheet. Investors also form their own opinion of Oncternal Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Oncternal Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncternal Therapeutics' market value can be influenced by many factors that don't directly affect Oncternal Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oncternal Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncternal Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncternal Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.